There is a strong connection between inflammation, altered microRNA (miRNA) expression and colon cancer. Longstanding inflammatory bowel diseases-related colitis leads to increased risk for the development of colorectal cancer (CRC), while sporadic CRC is in part driven by the inflammatory microenvironment. This supports a causative role for inflammation in colon carcinogenesis. miRNAs are a class of small noncoding RNAs that have recently emerged as key players in both inflammation and cancer. Some miRNAs act as inflammatory mediators, others can act as either oncogenes or tumor suppressors depending on the cellular environment in which they are expressed. In particular, miR-21 is an oncogenic miRNA that has been implicated as an inflammatory mediator and may promote inflammation-associated colon carcinogenesis. miRNAs have potential as biomarkers and therapeutic targets in CRC. They are currently being evaluated as early detection biomarkers and prognostic classifiers. Polymorphisms in miRNAs and miRNA-binding sites may alter one’s risk of CRC. This review will focus on the role of inflammation and miRNAs in colon carcinogenesis and discuss the potential for miRNAs and inflammatory genes to be used as biomarkers and therapeutic targets of CRC.

Keywords:
MicroRNA, Colorectal cancer, Inflammation, Biomarker, miR-21
1.
Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893–2917.
2.
Schetter AJ, Heegaard NH, Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37–49.
3.
Mantovani A, Allavena P, Sica A, et al: Cancer-related inflammation. Nature 2008;454:436–444.
4.
Farraye FA, Odze RD, Eaden J, et al: AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:746–774, 774.e1–4, quiz e712–743.
5.
Ullman TA, Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 2011;140:1807–1816.
6.
Kasinski AL, Slack FJ: MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011;11:849–864.
7.
Goel GA, Kandiel A, Achkar JP, et al: Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 2011;106:719–730.
8.
Ambs S, Bennett WP, Merriam WG, et al: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:86–88.
9.
Hussain SP, Amstad P, Raja K, et al: Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333–3337.
10.
Kim SF, Huri DA, Snyder SH: Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005;310:1966–1970.
11.
Collado M, Serrano M: The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472–476.
12.
Sohn JJ, Schetter AJ, Yfantis HG, et al: Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS ONE 2012;7:e44156.
13.
Fujita K, Mondal AM, Horikawa I, et al: p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009;11:1135–1142.
14.
Risques RA, Lai LA, Himmetoglu C, et al: Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res 2011;71:1669–1679.
15.
Terzic J, Grivennikov S, Karin E, et al: Inflammation and colon cancer. Gastroenterology 2010;138:2101–2114.e5.
16.
Schetter AJ, Nguyen GH, Bowman ED, et al: Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009;15:5878–5887.
17.
Wu F, Zikusoka M, Trindade A, et al: MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;135:1624–1635.e24.
18.
Pekow JR, Kwon JH: MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:187–193.
19.
Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257–2261.
20.
Schetter AJ, Harris CC: Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 2011;38:734–742.
21.
Krichevsky AM, Gabriely G: miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13:39–53.
22.
Hatley ME, Patrick DM, Garcia MR, et al: Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 2010;18:282–293.
23.
Medina PP, Nolde M, Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010;467:86–90.
24.
Seike M, Goto A, Okano T, et al: miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009;106:12085–12090.
25.
Yang CH, Yue J, Fan M, et al: IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010;70:8108–8116.
26.
Löffler D, Brocke-Heidrich K, Pfeifer G, et al: Interleukin-6 dependent survival of multiple myeloma cells involves the STAT3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330–1333.
27.
Iliopoulos D, Jaeger SA, Hirsch HA, et al: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493–506.
28.
Sachdeva M, Zhu S, Wu F, et al: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009;106:3207–3212.
29.
Chen X, Guo X, Zhang H, et al: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28:1385–1392.
30.
Ng EK, Tsang WP, Ng SS, et al: MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009;101:699–706.
31.
Xu N, Papagiannakopoulos T, Pan G, et al: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009;137:647–658.
32.
Strillacci A, Griffoni C, Sansone P, et al: miR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009;315:1439–1447.
33.
Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al: miR-17–92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009;101:707–714.
34.
Nagel R, le Sage C, Diosdado B, et al: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008;68:5795–5802.
35.
Valeri N, Gasparini P, Fabbri M, et al: Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010;107:6982–6987.
36.
Yu Y, Wang Y, Ren X, et al: Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Mol Cancer Res 2010;8:1633–1642.
37.
Ng EK, Chong WW, Jin H, et al: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375–1381.
38.
Huang Z, Huang D, Ni S, et al: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118–126.
39.
Pu XX, Huang GL, Guo HQ, et al: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010;25:1674–1680.
40.
Cheng H, Zhang L, Cogdell DE, et al: Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011;6:e17745.
41.
Dotan E, Cohen SJ: Challenges in the management of stage II colon cancer. Semin Oncol 2011;38:511–520.
42.
Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425–436.
43.
Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008;68:6416–6424.
44.
Karaayvaz M, Pal T, Song B, et al: Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011;10:340–347.
45.
Nishida N, Yokobori T, Mimori K, et al: MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 2011;38:1437–1443.
46.
Diaz R, Silva J, Garcia JM, et al: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008;47:794–802.
47.
Akcakaya P, Ekelund S, Kolosenko I, et al: miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011;39:311–318.
48.
Engstrom PF, Arnoletti JP, Benson AB 3rd, et al: NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 2009;7:778–831.
49.
Vilar E, Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010;7:153–162.
50.
Nakajima G, Hayashi K, Xi Y, et al: Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 2006;3:317–324.
51.
Zhang W, Winder T, Ning Y, et al: A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011;22:104–109.
52.
Xing J, Wan S, Zhou F, et al: Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012;21:217–227.
53.
Boni V, Zarate R, Villa JC, et al: Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 2010;11:429–436.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.